Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
University of Minnesota Medical School researchers have made a discovery which could lead to a new way of thinking about how disease pathogenesis in the liver is regulated, which is important for understanding the condition nonalcoholic fatty liver disease, which is incredibly common and growing.
Children's Hospital Colorado pediatric gastroenterologist, Michael Narkewicz, MD, recently shared results of the Prospective Study of Ultrasound to Predict Hepatic Cirrhosis in Cystic Fibrosis, which sought to determine if liver ultrasounds could identify children and adolescents with cystic fibrosis who are at greater risk of developing advanced liver disease.
Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure -- but now a study offers hope of early detection, and targets for new treatments.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease.
Physicians are encountering a growing number of younger patients who are testing positive for hepatitis C virus fueled largely by the opioid crisis impacting communities around the country.
Dr Mark McPhail from the Department of Inflammation Biology, School of Immunology & Microbial Sciences and Dr Vishal Patel from the Institute of Liver Studies at King's College Hospital have been awarded £2.3 million by the National Institute of Health Research Health Technology Assessment to lead a new UK wide multi-centre trial to treat liver disease.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
Researchers at Northeast Ohio Medical University studied the lifespan of mitochondrial proteins in a mouse model of fatty liver disease. Comparing the amount of protein between healthy mice and a mouse model of nonalcoholic fatty liver disease gave them an estimate of each protein's half-life.
Shionogi & Co., Ltd. announced today that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.
Routine oral care to treat gum disease may play a role in reducing inflammation and toxins in the blood and improving cognitive function in people with liver cirrhosis.
Pulmonary fibrosis is one of the most common and serious types of lung disease. Now NIBIB-funded researchers have developed an in vitro lung tissue-on-a-chip system that mimics lung fibrosis, offering rapid testing of potential new anti-fibrotic treatments.
Problems like obesity and alcoholism appear to chronically trigger in the liver a receptor known to amplify inflammation in response to invaders like bacteria, scientists report.
Since the first liver transplant in 1963, donated livers have been immersed in an icy cold fluid in a cold storage system for transport, similar in principle to ice chests used for picnics and trips to the beach.
A team of researchers from the School of Immunology and Microbial Sciences and the Dental Institute has secured a multi-million Euro award to conduct research into liver disease.
The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.
genedrive plc, a near patient molecular diagnostics company, and the Foundation for Innovation of New Diagnostics (FIND), announced today a study agreement for the performance evaluation of genedrive plc’s hepatitis C virus (HCV) Genedrive HCV ID Kit.
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV-;the virus that causes AIDS-;and the hepatitis C virus.
A new study has shown that genetic variation may increase the risk of severe liver damage in Caucasians with chronic hepatitis B infection.
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.